Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lamin A/C
is the most studied nucleoskeletal constituent.
Lamin A/C
expression indicates cell differentiation and is also a structural component of nuclear speckles, which are involved in gene expression regulation. Hypertonicity has been reported to induce renal epithelial cell differentiation and expression of TonEBP (NFAT5), a
transcriptional activator
of hypertonicity-induced gene transcription. In this paper, we investigate the effect of hypertonicity on lamin A/C expression in MDCK cells and the involvement of TonEBP. Hypertonicity increased lamin A/C expression and its distribution to nucleoplasm with speckled pattern. Microscopy showed codistribution of TonEBP and lamin A/C in nucleoplasmic speckles, and immunoprecipitation demonstrated their interaction. TonEBP silencing caused lamin A/C redistribution from nucleoplasmic speckles to the nuclear rim, followed by lamin decrease, thus showing that hypertonicity induces lamin A/C speckles through a TonEBP-dependent mechanism. We suggest that lamin A/C speckles could serve TonEBP as scaffold thus favoring its role in hypertonicity.
...
PMID:Hypertonic-induced lamin A/C synthesis and distribution to nucleoplasmic speckles is mediated by TonEBP/NFAT5 transcriptional activator. 1802 79
LMNA encodes nuclear
Lamin A/C
that tethers lamina-associated domains (LADs) to the nuclear periphery. Mutations in LMNA cause degenerative disorders including the premature aging disorder Hutchinson-Gilford progeria, but the mechanisms are unknown. We report that Ser22-phosphorylated (pS22)
Lamin A/C
was localized to the nuclear interior in human fibroblasts throughout the cell cycle. pS22-
Lamin A/C
interacted with a subset of putative active enhancers, not LADs, at locations co-bound by the
transcriptional activator
c-Jun. In progeria-patient fibroblasts, a subset of pS22-
Lamin A/C
-binding sites were lost, whereas new pS22-
Lamin A/C
-binding sites emerged in normally quiescent loci. New pS22-
Lamin A/C
binding was accompanied by increased histone acetylation, increased c-Jun binding, and upregulation of nearby genes implicated in progeria pathophysiology. These results suggest that
Lamin A/C
regulates gene expression by enhancer binding. Disruption of the gene regulatory rather than LAD tethering function of
Lamin A/C
may underlie the pathogenesis of disorders caused by LMNA mutations.
...
PMID:Phosphorylated Lamin A/C in the Nuclear Interior Binds Active Enhancers Associated with Abnormal Transcription in Progeria. 3220 59